Mineralys Therapeutics, Inc. (MLYS)
MLYS Stock Price Chart
Explore Mineralys Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze MLYS price movements and trends.
MLYS Company Profile
Discover essential business fundamentals and corporate details for Mineralys Therapeutics, Inc. (MLYS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Feb 2023
Employees
51.00
Website
https://mineralystx.comCEO
Jon Congleton
Description
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.
MLYS Financial Timeline
Browse a chronological timeline of Mineralys Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.57.
Earnings released on 6 May 2026
EPS came in at -$0.47 surpassing the estimated -$0.51 by +7.84%.
Earnings released on 12 Mar 2026
EPS came in at -$0.40 surpassing the estimated -$0.52 by +22.52%.
Earnings released on 10 Nov 2025
EPS came in at -$0.52 surpassing the estimated -$0.66 by +21.21%.
Earnings released on 12 Aug 2025
EPS came in at -$0.66 surpassing the estimated -$0.78 by +15.38%.
Earnings released on 12 May 2025
EPS came in at -$0.79 surpassing the estimated -$1.02 by +22.55%.
Earnings released on 12 Feb 2025
EPS came in at -$0.98 surpassing the estimated -$1.00 by +2.00%.
Earnings released on 11 Nov 2024
EPS came in at -$1.13 falling short of the estimated -$0.83 by -36.14%.
Earnings released on 13 Aug 2024
EPS came in at -$0.83 falling short of the estimated -$0.73 by -13.70%.
Earnings released on 9 May 2024
EPS came in at -$0.70 falling short of the estimated -$0.68 by -2.94%.
Earnings released on 21 Mar 2024
EPS came in at -$0.61 surpassing the estimated -$0.85 by +28.24%.
Earnings released on 7 Nov 2023
EPS came in at -$0.57 surpassing the estimated -$0.72 by +20.83%.
Earnings released on 7 Aug 2023
EPS came in at -$0.31 surpassing the estimated -$0.83 by +62.65%.
Earnings released on 15 May 2023
EPS came in at -$0.51 surpassing the estimated -$0.71 by +28.17%.
Earnings released on 15 Mar 2023
EPS came in at -$1.74 falling short of the estimated $1.72 by -201.16%.
Earnings released on 10 Feb 2023
EPS came in at -$1.29k .
Earnings released on 30 Jun 2022
EPS came in at -$0.35 .
Earnings released on 31 Mar 2022
EPS came in at -$0.41 .
Earnings released on 31 Dec 2021
EPS came in at -$0.18 .
MLYS Stock Performance
Access detailed MLYS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
